ORKA

In the past six months, Oruka Therapeutics reported positive Phase 2a results for ORKA-001, leading to a stock surge. The company announced an upsized public offering of $700 million, which temporarily declined the stock. Oruka and Halozyme announced a global collaboration and license agreement to develop ORKA-001 with Hypercon™ Technology. The company reported its Q4 and full year 2025 financial results, including $479.6 million in cash, cash equivalents, and marketable securities. Oruka Therapeutics has received a consensus rating of "Moderate Buy" from analysts. Insiders have sold $1.3 million worth of ORKA shares. The stock has seen a significant increase, rising over 113% year-to-date and over 571% in the past 12 months.